Larimar Therapeutics’ (LRMR) Buy Rating Reaffirmed at HC Wainwright

Posted by George Bondi on Jul 2nd, 2026

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 211.53% from the stock’s current price.

Several other equities research analysts also recently commented on LRMR. Wedbush dropped their target price on Larimar Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Tuesday, April 21st. JPMorgan Chase & Co. started coverage on shares of Larimar Therapeutics in a research note on Wednesday, May 27th. They issued an “overweight” rating and a $9.00 price target on the stock. Robert W. Baird cut their price objective on shares of Larimar Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Wall Street Zen upgraded shares of Larimar Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $12.71.

Read Our Latest Report on LRMR

Larimar Therapeutics Stock Performance

Shares of NASDAQ LRMR opened at $3.21 on Thursday. The company has a 50 day simple moving average of $3.70 and a two-hundred day simple moving average of $3.95. Larimar Therapeutics has a fifty-two week low of $2.71 and a fifty-two week high of $6.42. The company has a market capitalization of $333.45 million, a price-to-earnings ratio of -1.56 and a beta of 0.84.

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.22. On average, analysts forecast that Larimar Therapeutics will post -1.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Larimar Therapeutics

Several institutional investors have recently modified their holdings of LRMR. BNP Paribas Financial Markets raised its position in Larimar Therapeutics by 75.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock worth $33,000 after buying an additional 4,376 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Larimar Therapeutics during the 4th quarter valued at about $60,000. Sei Investments Co. grew its stake in shares of Larimar Therapeutics by 54.5% in the first quarter. Sei Investments Co. now owns 16,336 shares of the company’s stock worth $74,000 after acquiring an additional 5,763 shares during the period. Coldstream Capital Management Inc. bought a new stake in shares of Larimar Therapeutics in the third quarter worth approximately $57,000. Finally, Strs Ohio raised its holdings in shares of Larimar Therapeutics by 174.7% during the first quarter. Strs Ohio now owns 21,700 shares of the company’s stock valued at $98,000 after purchasing an additional 13,800 shares during the last quarter. 91.92% of the stock is owned by hedge funds and other institutional investors.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.